An expert committee of the Central Drugs Standard Control Organisation (CDSCO) on Wednesday sought additional safety and efficacy data for COVID-19 vaccine candidates of Serum Institute of India and Bharat Biotech after deliberating upon their applications seeking emergency use authorisation for the shots, officials said. The application by the Indian arm of US pharmaceutical firm Pfizer was not taken up for deliberation on Wednesday as the company sought more time for making a presentation before the committee, they said.
CNBC-TV18 has learnt that the government is likely to make use of the voters' list to identify the priority age group for the first phase of vaccination.
CNBC-TV18’s Timsy Jaipuria has more details.
Watch the video